Association between immune‐related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis
Fundamental & Clinical Pharmacology · 2024
DOI: 10.1111/fcp.12966 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Romain Euvrard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Interne et Pathologie Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, France. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICI) represent a breakthrough in oncology in terms of prognosis and safety. They now constitute a cornerstone in the management of metastatic melanoma. However, a new kind of adverse event called immune‐related adverse events (irAE) has emerged. These irAE could be conceptually considered as an indicator of the antitumoral immune response, but the association between irAE and prognosis is still a matter of debate.
Objective
The purpose of this study was to investigate the association between the overall survival (OS) and the prevalence of irAE in melanoma.
Methods
MEDLINE/PubMed, WebofScience, ClinicalTrials, and WHOTrials databases were searched to identify phase 3 randomized controlled trials (RCT) assessing ICI in melanoma and published up to April 2021. A weighted regression was performed to estimate this association according to standard method of surrogacy analysis.
Results
A total of 14 RCT including 7646 patients (median age: 59.3 years) with melanoma were included. All types of ICI were represented (ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, as well as ipilimumab and nivolumab combination). irAE were frequent but rarely fatal. The combination of ICI caused more irAE than anti‐PD1 (or PDL1) and anti‐CTLA4 monotherapies. No relationship was found between the occurrence of irAE and OS (beta coefficient 0.078, R 2 3%, p = 0.52), nor between cutaneous irAE and OS (beta coefficient 0.080, R 2 6%, p = 0.33).
Conclusion
Although limited by the heterogeneity of ICI included in the regression and the low number of included RCT, the present study suggests an absence of association between irAE and prognosis in melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Médecine Interne et Pathologie Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, France.
- Service de Médecine Interne et d'immunologie clinique, Université de Lyon 1, Hôpital Édouard Herriot, Hospices Civils de Lyon, Lyon, France.
- Equipe Évaluation et Modélisations des Effets Thérapeutiques, UMR CRNS 5558, Université Claude Bernard Lyon 1, Lyon, France.
- Lyon Immunopathology Federation (LIFe), Hospices Civils de Lyon, France.
- Service de Dermatologie, Hôpital Lyon Sud, Hospices Civils de Lyon, France.
- ImmuCare (Immunology Cancer Research), Hospices Civils de Lyon, France.
ORCID-Profile: Romain Euvrard
Zitieren
APA
Euvrard, R., Robert, M., Mainbourg, S., Dalle, S., & Lega, J. C. (2024). Association between immune‐related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12966
Vancouver
Euvrard R, Robert M, Mainbourg S, Dalle S, Lega JC. Association between immune‐related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12966
BibTeX
@article{Euvrard2024,
author = {Euvrard, Romain and Robert, Marie and Mainbourg, Sabine and Dalle, Stéphane and Lega, Jean-Christophe},
title = {Association between immune‐related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
doi = {10.1111/fcp.12966}
}
EUVIMED